Urinary Tract Infection Treatment Market Analysis By Drug Class (β-lactam, Azoles, Quinolones, Aminoglycosides), Clinical Indications (Urethritis, Cystitis, Pyelonephritis), by End User, Size Analysis, Share Value, Growth Analysis and Segmentation Till 2023
UTI Market Scope
The global Urinary tract infection treatment market size will approximately reach USD 9.89 billion by 2023. It can grow at a CAGR of 3.6% over the forecast period. Urinary tract infection (UTI) is caused by bacteria traveling up to the bladder and infecting the surrounding regions. It has been known to affect at least 60% women and 12% men once in their lifetime. Various treatments for bladder infections include antibiotics and a change in lifestyle habits. The global UTI treatment drugs market report by Market Research Future (MRFR) has been compiled with the help of experts in urology and includes predictions on upcoming developments from 2017 to 2023 (forecast period).
It stood at a valuation of USD 8 billion in 2016. Major drivers of the market include obesity, diabetes, and sexual intercourse. Urinary tract infection hospital visits account for close to USD 1 billion annually and 8.3 million visits annually. Due to complications with female anatomy, UTI has a chance of affecting females more than males.
Request Free Sample Copy: https://www.marketresearchfuture.com/sample_request/3146
Urinary catheters are deemed to be responsible for driving up UTI infections. Health awareness of women, old age, child birth, and nosocomial infections are expected to drive the UTI treatment market demand exponentially. Research and development for the treatment of complicated UTI (cUTI) combined with early diagnosis and patient-centric policies can bode well for the global UTI treatment drugs market. Approval of new drugs by regulatory agencies has been vital in propelling market growth. New assays such as fluorescence in-situ hybridization (FISH) and flow cytometry will assist healthcare providers with early diagnosis.
However, rising cases of infectious diseases due to catheter use, drug resistance, and unmet needs can hamper market growth.
UTI Market Segmentation
The global Urinary tract infection treatment market is segmented by drug class, clinical indications, and end users.
The global UTI treatment Market is segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles, and others. Quinolones accounted for close to 45% market share in 2016. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users, the market is segmented into hospitals and self-administered.
UTI Market Regional Analysis
Asia Pacific (APAC), Europe, the Middle East & Africa (MEA), and Americas are the regions considered the center of interest with respect to the global Urinary tract infection treatment market.
The Americas accounted for the largest market share in 2017. The U.S. is one of the biggest revenue generators due to being having one of the biggest healthcare spending rate. In addition, programs such as Medicare, Affordable Care Act, and Hospital Readmissions Reduction Program can take a toll on patient medical fees and negatively impact the market.
APAC can exhibit the fastest growth rate during the forecast period due to low cost of drugs, availability of generics, and a large patient pool. Healthcare applications are of prime importance in case of UTIs. Hospitals can assist UTI patients with the right prescriptions and eliminate waiting appointments. The resolve of pharmacies for providing testing kits and antibiotics can drive the market demand exponentially.
UTI Market Competition Outlook
Bayer AG, F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd., Novartis AG, Cipla Inc., Pfizer Inc., Johnson & Johnson, AstraZeneca, GlaxoSmithKline, and others are prominent names in the global UTI treatment market. Cost-effective solutions are being developed by players for keeping hospitals and other healthcare providers ready. For instance, AVYCAZ by Allergan was approved by the U.S. FDA for patients between the ages of 3 months to 18 years.
UTI Market Industry News
Cefiderocol (Fetroja) is a drug approved by the U.S. Food and Drug Administration for the treatment for certain UTIs. This has been triggered by the rise of antibiotic-resistant UTIs, with nearly 2.8 million cases registered in the U.S. alone.
Browse More Details at: https://www.marketresearchfuture.com/reports/uti-treatment-market-3146
Table of Content:
1 Urinary Tract Infection (UTI) Treatment Market Introduction
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Urinary Tract Infection Treatment Market Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Urinary Tract Infection Treatment Market Dynamics
3.5 Macroeconomic Indicators
4 Urinary Tract Infection Treatment Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
5 Global Urinary Tract Infection Drugs Market, By Drug Class
6 Global Urinary Tract Infection Drugs Market, By Clinical Indications
7 Global Urinary Tract Infection Drugs Market, By End User
8 Global UTI Drugs Market, By Country
8.4 Saudi Arabia
Browse Related Research Report at:
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar